Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 443

1.

Drawing the mind: Aesthetics of representing mental illness in select graphic memoirs.

Venkatesan S, Saji S.

Health (London). 2019 May 13:1363459319846930. doi: 10.1177/1363459319846930. [Epub ahead of print]

PMID:
31081388
2.

MLH1 germline mutation associated with Lynch syndrome in a family followed for more than 45 years.

Momma T, Gonda K, Akama Y, Endo E, Ujiie D, Fujita S, Maejima Y, Horita S, Shimomura K, Saji S, Kono K, Yashima R, Watanabe F, Sugano K, Nomizu T.

BMC Med Genet. 2019 May 2;20(1):67. doi: 10.1186/s12881-019-0792-0.

3.

Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication.

Ueno T, Saji S, Masuda N, Iwata H, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Sasano H, Toi M.

ESMO Open. 2019 Feb 27;4(1):e000476. doi: 10.1136/esmoopen-2018-000476. eCollection 2019.

4.

'It was nothing that you would think was anything': Qualitative analysis of appraisal and help seeking preceding brain cancer diagnosis.

Scott SE, Penfold C, Saji S, Curtis S, Watts C, Hamilton W, Joannides AJ, Walter FM.

PLoS One. 2019 Mar 22;14(3):e0213599. doi: 10.1371/journal.pone.0213599. eCollection 2019.

5.

Missed opportunities for diagnosing brain tumours in primary care: a qualitative study of patient experiences.

Walter FM, Penfold C, Joannides A, Saji S, Johnson M, Watts C, Brodbelt A, Jenkinson MD, Price SJ, Hamilton W, Scott SE.

Br J Gen Pract. 2019 Apr;69(681):e224-e235. doi: 10.3399/bjgp19X701861. Epub 2019 Mar 11.

6.

Progesterone receptor expression in proliferating cancer cells of hormone-receptor-positive breast cancer.

Ueno T, Saji S, Chiba T, Kamma H, Isaka H, Itoh H, Imi K, Miyamoto K, Tada M, Sasano H, Toi M, Imoto S.

Tumour Biol. 2018 Nov;40(10):1010428318811025. doi: 10.1177/1010428318811025.

PMID:
30841783
7.

Phase III randomised trial comparing 6 vs. 12-month of capecitabine as adjuvant chemotherapy for patients with stage III colon cancer: final results of the JFMC37-0801 study.

Tomita N, Kunieda K, Maeda A, Hamada C, Yamanaka T, Sato T, Yoshida K, Boku N, Nezu R, Yamaguchi S, Mishima H, Sadahiro S, Muro K, Ishiguro M, Sakamoto J, Saji S, Maehara Y.

Br J Cancer. 2019 Apr;120(7):689-696. doi: 10.1038/s41416-019-0410-0. Epub 2019 Mar 5.

PMID:
30833647
8.

Differential Involvement of Autophagy and Apoptosis in Response to Chemoendocrine and Endocrine Therapy in Breast Cancer: JBCRG-07TR.

Ueno T, Masuda N, Kamigaki S, Morimoto T, Saji S, Imoto S, Sasano H, Toi M.

Int J Mol Sci. 2019 Feb 24;20(4). pii: E984. doi: 10.3390/ijms20040984.

9.

Daikenchuto accelerates the recovery from prolonged postoperative ileus after open abdominal surgery: a subgroup analysis of three randomized controlled trials.

Kono T, Shimada M, Nishi M, Morine Y, Yoshikawa K, Katsuno H, Maeda K, Koeda K, Morita S, Watanabe M, Kusano M, Sakamoto J, Saji S, Sokuoka H, Sato Y, Maehara Y, Kanematsu T, Kitajima M.

Surg Today. 2019 Feb 25. doi: 10.1007/s00595-019-01787-9. [Epub ahead of print]

PMID:
30805720
10.

Characteristics of adverse events of endocrine therapies among older patients with breast cancer.

Honma N, Makita M, Saji S, Mikami T, Ogata H, Horii R, Akiyama F, Iwase T, Ohno S.

Support Care Cancer. 2019 Feb 7. doi: 10.1007/s00520-019-04674-8. [Epub ahead of print]

PMID:
30729298
11.

Altered expression of p63 isoforms and expansion of p63- and club cell secretory protein-positive epithelial cells in the lung as novel features of aging.

Fukumoto J, Sidramagowda Patil S, Krishnamurthy S, Saji S, John I, Narala VR, Hernández-Cuervo H, Alleyn M, Breitzig MT, Galam L, Soundararajan R, Chaudhari UK, Hansen BC, Lockey RF, Kolliputi N.

Am J Physiol Cell Physiol. 2019 Apr 1;316(4):C492-C508. doi: 10.1152/ajpcell.00330.2018. Epub 2019 Jan 16.

PMID:
30649915
12.

Estradiol promotes rapid degradation of HER3 in ER-positive breast cancer cell line MCF-7.

Suga J, Izumiyama K, Tanaka N, Saji S.

Biochem Biophys Rep. 2018 Oct 26;16:103-109. doi: 10.1016/j.bbrep.2018.10.008. eCollection 2018 Dec.

13.

[A Case of Recurrent Colon Cancer with Peritoneal Dissemination Treated with Aflibercept Showing Partial Response for One Year].

Gonda K, Fujita S, Shibata M, Hatakeyama Y, Tachiya Y, Rokkaku Y, Saze Z, Momma T, Ohki S, Saji S, Kono K.

Gan To Kagaku Ryoho. 2018 Oct;45(10):1539-1542. Japanese.

PMID:
30382071
14.

Poland syndrome accompanied by internal iliac artery supply disruption sequence: a case report.

Gonda K, Tachiya Y, Hatakeyama Y, Momma T, Tamaoki T, Maejima Y, Rokkaku Y, Saji S, Shimomura K, Kono K.

J Med Case Rep. 2018 Oct 26;12(1):312. doi: 10.1186/s13256-018-1823-8.

15.

Color-coded Imaging of the Circulating Tumor Cell Microenvironment.

Satake T, Suetsugu A, Nakamura M, Kunisada T, Shimizu M, Saji S, Moriwaki H, Hoffman RM.

Anticancer Res. 2018 Oct;38(10):5635-5638. doi: 10.21873/anticanres.12898.

PMID:
30275181
16.

A randomized phase III study of hepatic arterial infusion chemotherapy with 5-fluorouracil and subsequent systemic chemotherapy versus systemic chemotherapy alone for colorectal cancer patients with curatively resected liver metastases (Japanese Foundation for Multidisciplinary Treatment of Cancer 32).

Kusano M, Aoyama T, Okabayashi K, Hirata K, Tsuji Y, Nakamori S, Asahara T, Ohashi Y, Yoshikawa T, Sakamoto J, Oba K, Saji S.

J Cancer Res Ther. 2018 Sep;14(Supplement):S761-S766. doi: 10.4103/0973-1482.179188.

17.

Graphic Medicine and the Limits of Biostatistics.

Venkatesan S, Saji S.

AMA J Ethics. 2018 Sep 1;20(9):E897-901. doi: 10.1001/amajethics.2018.897.

18.

FTIR characterization of the setting reaction of biodentine™.

Alotaibi J, Saji S, Swain MV.

Dent Mater. 2018 Nov;34(11):1645-1651. doi: 10.1016/j.dental.2018.08.294. Epub 2018 Sep 12.

PMID:
30219594
19.

(Un)bridgeable Chasms?: Doctor-Patient Interactions in Select Graphic Medical Narratives.

Venkatesan S, Saji S.

J Med Humanit. 2018 Aug 17. doi: 10.1007/s10912-018-9528-y. [Epub ahead of print]

PMID:
30117008
20.

Color-coded Imaging Distinguishes Cancer Cells, Stromal Cells, and Recombinant Cancer-stromal Cells in the Tumor Microenvironment During Metastasis.

Nakamura M, Suetsugu A, Hasegawa K, Satake T, Kunisada T, Shimizu M, Saji S, Moriwaki H, Hoffman RM.

Anticancer Res. 2018 Aug;38(8):4417-4423. doi: 10.21873/anticanres.12743.

PMID:
30061205
21.

A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study.

Yamamoto Y, Iwata H, Ueno T, Taira N, Kashiwaba M, Takahashi M, Tada H, Tsugawa K, Toyama T, Niikura N, Hara F, Fujisawa T, Yoshinami T, Saji S, Takano T, Masuda N, Morita S, Toi M, Ohno S.

Jpn J Clin Oncol. 2018 Sep 1;48(9):855-859. doi: 10.1093/jjco/hyy097.

PMID:
30020510
22.

Long isoform of VEGF stimulates cell migration of breast cancer by filopodia formation via NRP1/ARHGAP17/Cdc42 regulatory network.

Kiso M, Tanaka S, Saji S, Toi M, Sato F.

Int J Cancer. 2018 Dec 1;143(11):2905-2918. doi: 10.1002/ijc.31645. Epub 2018 Oct 9.

23.

Neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study.

Sato N, Masuda N, Morimoto T, Ueno T, Kanbayashi C, Kaneko K, Yasojima H, Saji S, Sasano H, Morita S, Ohno S, Toi M.

Cancer Med. 2018 Jun 14. doi: 10.1002/cam4.1600. [Epub ahead of print]

24.

Evidence that metallic proxies are unsuitable for assessing the mechanics of microwear formation and a new theory of the meaning of microwear.

van Casteren A, Lucas PW, Strait DS, Michael S, Bierwisch N, Schwarzer N, Al-Fadhalah KJ, Almusallam AS, Thai LA, Saji S, Shekeban A, Swain MV.

R Soc Open Sci. 2018 May 23;5(5):171699. doi: 10.1098/rsos.171699. eCollection 2018 May.

25.

The long and winding road for overcoming resistance to hormone therapy in breast cancer.

Saji S.

Breast Cancer. 2018 Jul;25(4):377-378. doi: 10.1007/s12282-018-0876-2. No abstract available.

PMID:
29808354
26.

Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer.

Kotaka M, Yamanaka T, Yoshino T, Manaka D, Eto T, Hasegawa J, Takagane A, Nakamura M, Kato T, Munemoto Y, Nakamura F, Bando H, Taniguchi H, Gamoh M, Shiozawa M, Saji S, Maehara Y, Mizushima T, Ohtsu A, Mori M.

ESMO Open. 2018 Apr 24;3(3):e000354. doi: 10.1136/esmoopen-2018-000354. eCollection 2018.

27.

Curcumin-galactomannoside complex inhibits pathogenesis in Ox-LDL-challenged human peripheral blood mononuclear cells.

Saji S, Asha S, Svenia PJ, Ratheesh M, Sheethal S, Sandya S, Krishnakumar IM.

Inflammopharmacology. 2018 Oct;26(5):1273-1282. doi: 10.1007/s10787-018-0474-0. Epub 2018 Apr 9.

PMID:
29633105
28.

Differential Organ-targeting and Cellular Characteristics of Metastatic Human Pancreatic Cancer Cell Lines in Mouse Models.

Satake T, Suetsugu A, Nakamura M, Hasegawa K, Kunisada T, Shimizu M, Saji S, Moriwaki H, Hoffman RM.

Anticancer Res. 2018 Apr;38(4):1927-1935.

PMID:
29599308
29.

Visualizing the Tumor Microenvironment by Color-coded Imaging in Orthotopic Mouse Models of Cancer.

Suetsugu A, Shimizu M, Saji S, Moriwaki H, Hoffman RM.

Anticancer Res. 2018 Apr;38(4):1847-1857. Review.

PMID:
29599301
30.

The relationship between serum E2 levels and recurrence in premenopausal, ER-positive breast cancer patients: A retrospective study.

Takuwa H, Saji S, Takada M, Takahara S, Yamauchi A.

Breast Dis. 2018;37(4):185-190. doi: 10.3233/BD-170307.

PMID:
29578459
31.

Risk Factors for Peritoneal Recurrence in Stage II to III Colon Cancer.

Mayanagi S, Kashiwabara K, Honda M, Oba K, Aoyama T, Kanda M, Maeda H, Hamada C, Sadahiro S, Sakamoto J, Saji S, Yoshikawa T.

Dis Colon Rectum. 2018 Jul;61(7):803-808. doi: 10.1097/DCR.0000000000001002.

32.

Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial.

Ueno T, Saji S, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Yamanaka T, Sasano H, Toi M.

ESMO Open. 2018 Feb 14;3(2):e000314. doi: 10.1136/esmoopen-2017-000314. eCollection 2018.

33.

Clinical Signatures of Mucinous and Poorly Differentiated Subtypes of Colorectal Adenocarcinomas by a Propensity Score Analysis of an Independent Patient Database from Three Phase III Trials.

Kanda M, Oba K, Aoyama T, Kashiwabara K, Mayanagi S, Maeda H, Honda M, Hamada C, Sadahiro S, Sakamoto J, Saji S, Yoshikawa T; Japanese Foundation for Multidisciplinary Treatment of Cancer.

Dis Colon Rectum. 2018 Apr;61(4):461-471. doi: 10.1097/DCR.0000000000001022.

PMID:
29521828
34.

A Case of Squamous Cell Carcinoma of Unknown Primary that Responded to the Multi-Tyrosine Kinase Inhibitor Lenvatinib.

Kimura-Tsuchiya R, Sasaki E, Nakamura I, Suzuki S, Kawana S, Okouchi C, Fukushima T, Hashimoto Y, Suzuki S, Saji S.

Case Rep Oncol. 2018 Feb 9;11(1):75-80. doi: 10.1159/000486569. eCollection 2018 Jan-Apr.

35.

Impact of physiological hormonal fluctuations on 18F-fluorodeoxyglucose uptake in breast cancer.

Miyake KK, Nakamoto Y, Saji S, Sugie T, Kurihara K, Kanao S, Ikeda DM, Toi M, Togashi K.

Breast Cancer Res Treat. 2018 Jun;169(3):437-446. doi: 10.1007/s10549-018-4711-4. Epub 2018 Feb 8.

PMID:
29423901
36.

Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer.

Ogiya R, Niikura N, Kumaki N, Yasojima H, Iwasa T, Kanbayashi C, Oshitanai R, Tsuneizumi M, Watanabe KI, Matsui A, Fujisawa T, Saji S, Masuda N, Tokuda Y, Iwata H.

Oncotarget. 2017 Oct 27;8(61):103671-103681. doi: 10.18632/oncotarget.22110. eCollection 2017 Nov 28.

37.

Development and validation of a prognostic nomogram for colorectal cancer after radical resection based on individual patient data from three large-scale phase III trials.

Honda M, Oba K, Akiyoshi T, Maeda H, Kashiwabara K, Kanda M, Mayanagi S, Aoyama T, Hamada C, Sadahiro S, Fukunaga Y, Ueno M, Sakamoto J, Saji S, Yoshikawa T.

Oncotarget. 2017 Oct 12;8(58):99150-99160. doi: 10.18632/oncotarget.21845. eCollection 2017 Nov 17.

38.

Hazard rate of tumor recurrence over time in patients with colon cancer: implications for postoperative surveillance from three Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) clinical trials.

Maeda H, Kashiwabara K, Aoyama T, Oba K, Honda M, Mayanagi S, Kanda M, Hamada C, Sadahiro S, Sakamoto J, Saji S, Yoshikawa T.

J Cancer. 2017 Oct 23;8(19):4057-4064. doi: 10.7150/jca.21365. eCollection 2017.

39.

A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S-1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG-M01 study).

Ishiguro H, Saji S, Nomura S, Tanaka S, Ueno T, Onoue M, Iwata H, Yamanaka T, Sasaki Y, Toi M.

Cancer Med. 2017 Dec;6(12):2909-2917. doi: 10.1002/cam4.1258. Epub 2017 Nov 13.

40.

Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with post-menopausal estrogen receptor-positive advanced breast cancer: a sub-group analysis of the JBCRG-C06 Safari study.

Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita T, Yamamoto Y, Yotsumoto D, Toi M, Ohno S.

Curr Med Res Opin. 2018 Jan;34(1):49-54. doi: 10.1080/03007995.2017.1400426. Epub 2017 Nov 21.

PMID:
29095648
41.

Randomized phase III trial comparing surgery alone to UFT + PSK for stage II rectal cancer (JFMC38 trial).

Okuno K, Aoyama T, Oba K, Yokoyama N, Matsuhashi N, Kunieda K, Nishimura Y, Akamatsu H, Kobatake T, Morita S, Yoshikawa T, Sakamoto J, Saji S.

Cancer Chemother Pharmacol. 2018 Jan;81(1):65-71. doi: 10.1007/s00280-017-3466-7. Epub 2017 Nov 1.

42.

Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm.

Sawaki A, Yamada Y, Yamaguchi K, Nishina T, Doi T, Satoh T, Chin K, Boku N, Omuro Y, Komatsu Y, Hamamoto Y, Koizumi W, Saji S, Shah MA, Van Cutsem E, Kang YK, Iwasaki J, Kuriki H, Ohtsuka W, Ohtsu A.

Gastric Cancer. 2018 May;21(3):429-438. doi: 10.1007/s10120-017-0773-y. Epub 2017 Oct 20.

43.

Clinical impact of tumor location on the colon cancer survival and recurrence: analyses of pooled data from three large phase III randomized clinical trials.

Aoyama T, Kashiwabara K, Oba K, Honda M, Sadahiro S, Hamada C, Maeda H, Mayanagi S, Kanda M, Sakamoto J, Saji S, Yoshikawa T.

Cancer Med. 2017 Nov;6(11):2523-2530. doi: 10.1002/cam4.1208. Epub 2017 Sep 25.

44.

Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis.

Niikura N, Shimomura A, Fukatsu Y, Sawaki M, Ogiya R, Yasojima H, Fujisawa T, Yamamoto M, Tsuneizumi M, Kitani A, Watanabe J, Matsui A, Takahashi Y, Takashima S, Shien T, Tamura K, Saji S, Masuda N, Tokuda Y, Iwata H.

Breast Cancer Res Treat. 2018 Jan;167(1):81-87. doi: 10.1007/s10549-017-4489-9. Epub 2017 Sep 11.

PMID:
28895005
45.

[III. Novel Endocrine Therapy with Signal Transduction Inhibitors for Hormone Dependent Breast Cancer].

Tachibana K, Ohtake T, Saji S.

Gan To Kagaku Ryoho. 2016 Dec;43(13):2509-2512. Japanese. No abstract available.

PMID:
28676614
46.

Imaging the Role of Multinucleate Pancreatic Cancer Cells and Cancer-Associated Fibroblasts in Peritoneal Metastasis in Mouse Models.

Hasegawa K, Suetsugu A, Nakamura M, Matsumoto T, Aoki H, Kunisada T, Shimizu M, Saji S, Moriwaki H, Hoffman RM.

Anticancer Res. 2017 Jul;37(7):3435-3440.

PMID:
28668832
47.

Choline-Deficient-Diet-Induced Fatty Liver Is a Metastasis-Resistant Microenvironment.

Nakamura M, Suetsugu A, Hasegawa K, Matsumoto T, Aoki H, Kunisada T, Shimizu M, Saji S, Moriwaki H, Hoffman RM.

Anticancer Res. 2017 Jul;37(7):3429-3434.

PMID:
28668831
48.

Randomized phase II study of daily and alternate-day administration of S-1 for advanced gastric cancer (JFMC43-1003).

Tanaka H, Kanda M, Morita S, Taguri M, Nishikawa K, Shimada M, Muguruma K, Koeda K, Takahashi M, Nakamori M, Konno H, Tsuji A, Hosoya Y, Shirasaka T, Yamamitsu S, Sowa M, Kitajima M, Okajima M, Kobayashi M, Sakamoto J, Saji S, Hirakawa K.

Int J Clin Oncol. 2017 Dec;22(6):1052-1059. doi: 10.1007/s10147-017-1157-3. Epub 2017 Jun 30.

49.

Impact of postoperative complications on the colorectal cancer survival and recurrence: analyses of pooled individual patients' data from three large phase III randomized trials.

Aoyama T, Oba K, Honda M, Sadahiro S, Hamada C, Mayanagi S, Kanda M, Maeda H, Kashiwabara K, Sakamoto J, Saji S, Yoshikawa T.

Cancer Med. 2017 Jul;6(7):1573-1580. doi: 10.1002/cam4.1126. Epub 2017 Jun 22.

50.

Breast cancer patient delay in Fukushima, Japan following the 2011 triple disaster: a long-term retrospective study.

Ozaki A, Nomura S, Leppold C, Tsubokura M, Tanimoto T, Yokota T, Saji S, Sawano T, Tsukada M, Morita T, Ochi S, Kato S, Kami M, Nemoto T, Kanazawa Y, Ohira H.

BMC Cancer. 2017 Jun 19;17(1):423. doi: 10.1186/s12885-017-3412-4.

Supplemental Content

Support Center